I think Navin Flourine International deserves some research. I first noted this company in 2011 when it’s dividend yield was quite high on common screening websites (due to special dividend). I made a small investment and found that carbon credits were a good source of revenue. Since then, the stock has gone up like 3x and currently trading around 950 levels.
Last few important developments:
a) Acquisition of Manchester Organics UK (2011)
b) CRAMS business (2011)
c) 120 Crore JV with Piramal Enterprises at Dahej (Specialty Flourochemicals focussed on healthcare. Navin has 49%)
As of now, CRAMS contributes just 6% revenue on standalone, Refrigerants-36%, Specialty chemicals - 39%. Inorganic Flourides -19%. (All this in latest presentation)
Some data from latest Ambit report (17-June-15) which analyzed Gujrat Flourine in report titled inox power
One of my concerns has been - low ROE inspite of generous dividends. But I believe this company deserves a closer inspection. Institutional investors like DSP Microcap Fund, Atyant Capital, hold some shares (above 2%)
Highlights of the Concall by Capital Mkt
Net revenues rose 16% to Rs 150 crore for Q1FY’16 on a YoY basis while EBITDA increased 117% to Rs 26 crore and PAT jumped 113% to Rs 18 crore.EBITDA margin of the company improved to 17% in Q1FY’16 from 9% in Q1FY’15 mainly on account of operating leverage.Revenue growth across business units was driven by higher volumes and better realizations
Refrigerants revenue increased 22% on a YoY basis in Q1FY’16 to Rs 61 crore and 24% on a QoQ basis. Domestic revenues were 59% while exports were 41%.Inorganic fluorides revenue decreased 8% on a YoY basis in Q1FY’16 to Rs 24 crore and 4% on a QoQ basis. Domestic revenues were 87% while exports were13%.Speciality chemicals revenue increased 22% on a YoY basis in Q1FY’16 to Rs 55 crore but decreased 4% on a QoQ basis. Domestic revenues were 55% while exports were45%.
CRAMS revenue decreased 8% on a YoY basis in Q1FY’16 to Rs 10 crore but decreased 38% on a QoQ basis. This segment has only export revenues.Greenfield Facility at Dahej, Gujarat, a joint venture project at Dahej with Piramal Enterprises to develop, manufacture and sell speciality Fluorochemicals for healthcare segment is expected to come on-stream by H2FY16 with an investments of around Rs.140 croreDemand for refrigerant has surged substantially leading to improved realizations. Increasing usage of R22 in pharmaceutical companies and agro chemical companies as feed stock is also augmenting demand. Overseas demand for R22 has remained stable.
Speciality chemicals continued its good growth in both domestic and overseas market.Inorganic chemicals growth was flat during the quarter as this BU was impacted by the weak domestic steel industry. However the company is now targeting exports market.CRAMS business has performed in line with expectations with clear visibility of the order book supporting its growth
Capex completed for manufacturing facility for multi ton batch size for CRAMS business unit at Devas at an investment of Rs. 60 crore .New facilities will be India’s only plant with high pressure fluorination and cGMP complaint capabilities. Customer audit for the business is under way and it is getting a positive response.Benefits of capex at devas would be seen at later part of the year.
Surprised that this company has not got the attention it deserves yet. The management has shown superior capital allocation skills and is increasingly focusing on the crams and spec chem business. No incremental capex is being done in r22 refrigerants business which is expected to act as a cash cow for the next few years. The cash would be reinvested in high roce crams business. With agrochemicals cycle turning around the only headwind I see is the flourspar prices currently
Revenue grew by 6 % to Rs 226 Cr compare to 212 Cr in Q3FY18
EBITDA grew by 2 % to 52.4 Cr compare to 51.5 Cr in Q3FY18
EBITDA margin stood at 23.2 % for the quarter
PBT grew by 2 % to 45.9 Cr from 45.1 Cr in Q3FY18.
PBT margin stood at 20.3 % for the quarter
Gas business revenue grew by 8 % to 57 Cr from 53 Cr Q3FY18
Inorganic business Segment
Revenue grew by 24 % to 47 Cr compare to 38 Cr in Q3FY18
Specialty Chemical Business
Revenue grew by more than 40 % in Q3FY19 to 73 Cr as compare to 56 Cr in Q3FY18.
Revenue stood at 49 Cr compare to 64 Cr last year same quarter
Nine Month FY19
Revenue grew by 17 % to 711 Cr compare to 609 Cr in Q3FY18.
EBITDA grew by 8 % to 153.8 Cr compare to 165.9 Cr in nine month FY19.
EBITDA margin stood at 23.3 %.
PBT grew by 9 % to 146.4 Cr from 134.5 Cr in nine month DY18.
PBT margin stood at 20.6 %.
Revenue grew by 12 % to 197 Cr compare to 175 Cr last year Nine month
Contributed 28 % to overall sales in which 45 % revenue come from exports.
Revenues grew by 40 % to 146 Cr compare to 104 Cr last year Nine month.
Contributed 21 % to the overall sales of which exports was 10 %.
Specialty Chemical Business
Revenue grew by 41 % to 232 Cr compare to 155 Cr in nine month FY18.
Contributed 33 % to overall sales in which 41 % was exports.
Revenue stood at 135 Cr compare to 163 Cr last year same period.
It contributed 19 % to the overall sales and it was 100 % export.
Operating EBITDA growth of 4 % and margin expanded to 40 basis points to 23 % for the quarter compare to last quarter
Taken price hike with 3 customers
All business had done well except Cramps, Cramps exclude the Dahej operation and it impacted due to shift of campaigns into next fiscal year
Operating performance was impacted due to significant improvement in the raw material prices specifically for Q3.
On refrigerant Gas in this particular quarter there was strong demand in domestic markets. Export have perform well both in terms of volume as well as price realization.
On Inorganic fluoride there was demand from the domestic steel industry somewhat flat but growth in the Glass Industry remain very robust. On export front company have completed successful trials with customers in Korea and also some other new customers company have develop in japan.
Specialty chemical show significant growth on the back of efforts to increase domestic sales primarily driven by demand from the pharmaceutical segment. The export segment which is mainly towards the agro chemical industry also improved both in terms of volume as well as prices. Company did price increases across the products across the markets in the specialty chemical segment.
Cramps business impacted due to push back of campaign of few of company customer to next financial year which has shown slowdown in overall growth. CAPEX in Dahej is progressing well and as per schedule.
Company is continuously building its project pipeline. For new unit and capacity expansion will be as per expectation.
Company is extremely positive on Crams business.
Normal margin expectation will be in range of 22-24 %
Raw material price continues on increasing trend
In coming financial year company will be working on full utilisation level.
Navin Fluorine announces $410 million multi-year contract with a global company
Navin Fluorine International Limited (‘Navin Fluorine’), one of the largest
manufacturers of fluorochemicals, announced today that it has entered into a $ 410 million (~ 2900
Crores at current exchange rate) contract with a global company for manufacture and supply of a High
Performance Product (‘HPP’) in the fluorochemicals space. The contract is for a period of 7 years and
this product is not part of Navin Fluorine’s existing product portfolio. The capex and project will be
executed through its wholly owned subsidiary, Navin Fluorine Advanced Sciences Limited (‘NFASL’).
Navin Fluorine, through NFASL, will be investing$ 51.5 million(~ 365.50 Crores at current exchange
rate) to set up dedicated manufacturing facility and approximately$ 10 million(~ 71 Crores at current
exchange rate) to set up a captive power plant. The facility will be located at Dahej, in the state of
Gujarat and will be funded through a mix of internal accruals and debt. The supplies are expected to
commence from Q4 of FY22.
Commenting on this Mr. Radhesh Welling, Managing Director of Navin Fluorine said: 'This
Agreement, which represents Navin Fluorine’s largest contract to date, continues to establish us as a
leader in production and delivery of high-performance products within fluorination space.
This Agreement will help further expand our product portfolio and it reinforces the trust global
customers have in Navin Fluorine’s capabilities. It is testament to our deep and wide fluorine
experience and our strength in successfully scaling up of complex chemistries.
This is beginning of our entry into higher value HPP segment and we shall continue to add more
products in this segment."
Does the market know
what is the product?
who is the buyer?
when will commercial production start?
when will contracted supplies start?
what happens if there is a delay in commissioning?
what happens if the contracted buyer rescinds the contract?
what is the input material?
what happens if the input costs go up?
Is the product/ process under patent ?
What happens if some competitor gets a stay.?
So many unanswered questions and the stock is up 20%!!
The possibility of thinking market dosent know anything will be wrong, Market is always ahead, my sense is 2900cr is the contract , so if that comes in in a few years time also, there is visibility of revenue for the future on top of the current revenue.
20% upmove surely is a bit of overreaction for the size of the order , but market also starts extrapolation in such cases. And clearly , this supplements the uptick already shown by the company in terms of sales , magin and earnings growth in last few years. Also, market would be very volatile for chemical stocks during the current china situation.